Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
Oncoimmunology|December 10, 2020
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinomaChristopher Montemagno, Anais Hagege, Delphine Borchiellini, et al.
Cancer Treatment Reviews|October 10, 2018
Management of non-metastatic castrate-resistant prostate cancer: A systematic reviewYohann Loriot, Stéphane Supiot, Jean-Baptiste Beauval, et al.
Nature Reviews. Urology|May 17, 2018
Systemic treatments for high-risk localized prostate cancerGéraldine Pignot, Denis Maillet, Emmanuel Gross, et al.
Leukemia & Lymphoma|January 8, 2015
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphomaNicolas Martin, Delphine Borchiellini, Diane Coso, et al.
Critical Reviews in Oncology/Hematology|February 21, 2018
Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUGJean-Baptiste Beauval, Yohann Loriot, Christophe Hennequin, et al.
Clinical Kidney Journal|September 26, 2022
Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control studyAlexandre O Gérard, Susana Barbosa, Nadège Parassol, et al.
Pharmaceutics|February 25, 2023
Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate CancerJean-Marc Ferrero, Hakim Mahammedi, Gwenaelle Gravis, et al.
Theranostics|March 9, 2026
Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancerManon Teisseire, Arthur Karaulic, Julien Parola, et al.
Bulletin Du Cancer|December 20, 2025
[A 2025 inventory in oncology news]Stéphane Vignot, Audrey Bellesoeur, Delphine Borchiellini, et al.
Theranostics|March 15, 2019
Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5Sandy Giuliano, Maeva Dufies, Papa Diogop Ndiaye, et al.
Pageof 8